ODN 2216 

ODN 2216 is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. ODN 2216 induces high amounts of IFN-α and IFN-β. ODN 2216 induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 can activate NK cells and promote IFN-γ production of TCR-triggered CD4⁺ T cells^{[1][2][3][4][5]}.

ODN 2216 (6 μg/mL, 9 days) drives Th1 development of naive CD4 T cells^[1].
ODN 2216 (2 μM, 15 h) significantly decreased apoptosis of thymic DC^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ODN 2216 induces T-cell mediated antitumor immune response in murine vaccination models^[3]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

6432.00

332437-00-0

Solid

White to off-white

DNA, d(G-sp-G-sp-G-G-G-A-C-G-A-T-C-G-T-C-G-sp-G-sp-G-sp-G-sp-G-sp-G)

[DNA, d(G-sp-G-sp-G-G-G-A-C-G-A-T-C-G-T-C-G-sp-G-sp-G-sp-G-sp-G-sp-G)]

Room temperature in continental US; may vary elsewhere.

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Krug A, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001 Jul;31(7):2154-63.  [Content Brief]

  [2]. Okada T, et al. Murine thymic plasmacytoid dendritic cells. Eur J Immunol. 2003 Apr;33(4):1012-9.  [Content Brief]

  [3]. Huang L, et al. CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner. Oncogene. 2017 Jul 13;36(28):4081-4086.  [Content Brief]

  [4]. He Y, et al. Hepatic mitochondrial DNA/Toll-like receptor 9/MicroRNA-223 forms a negative feedback loop to limit neutrophil overactivation and acetaminophen hepatotoxicity in mice. Hepatology. 2017 Jul;66(1):220-234.  [Content Brief]

  [5]. Li Y, et al. A novel antagonist of TLR9 blocking all classes of immunostimulatory CpG-ODNs. Vaccine. 2011 Mar 3;29(11):2193-8.  [Content Brief]